| Market Capitalization (Millions $) |
20,562 |
| Shares
Outstanding (Millions) |
135 |
| Employees |
3,293 |
| Revenues (TTM) (Millions $) |
1,831 |
| Net Income (TTM) (Millions $) |
-190 |
| Cash Flow (TTM) (Millions $) |
160 |
| Capital Exp. (TTM) (Millions $) |
68 |
Natera Inc
Natera Inc is a multinational healthcare company that specializes in genetic testing and diagnostic solutions. Founded in 2003, the company is headquartered in San Carlos, California, but has operations across the United States, Europe, and Asia. Natera is publicly traded on the NASDAQ and currently employs over 1,200 people worldwide. The company's mission is to improve the lives of millions of patients and families by providing them with advanced genetic testing and diagnostics.
Natera offers a range of genetic testing solutions that enable healthcare providers to diagnose, monitor, and manage various health conditions. The company specializes in non-invasive prenatal testing (NIPT), which uses cell-free DNA (cfDNA) technology to detect certain genetic abnormalities in the fetus without the need for invasive procedures. The company's flagship product, Panorama, is a market-leading NIPT test that screens for common chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome.
In addition to NIPT, Natera provides a range of other genetic testing solutions for reproductive health, oncology, and organ transplantation. The company's products include tests for hereditary cancer risk assessment, inherited cardiovascular conditions, and reproductive genetics. Natera also offers a liquid biopsy test, Signatera, that detects the presence of circulating tumor DNA in cancer patients, providing insight into disease progression and treatment efficacy.
Beyond its focus on genetic testing and diagnostics, Natera is also engaged in research and development activities aimed at advancing the field of genomics. The company has partnerships with leading academic and research institutions and invests heavily in innovation and technology development. Natera has a portfolio of more than 300 issued and pending patents and has won numerous awards for its pioneering work in genomics.
In recent years, Natera has experienced significant growth, driven by rising demand for genetic testing and a growing trend towards personalized medicine. The company's financial performance has been strong, with revenues of $355.6 million in 2020, up from $302.3 million in 2019. Natera is committed to continued growth and expansion across its key markets, with a focus on advancing its technology, expanding its product offerings, and increasing market share.
Company Address: 13011 McCallen Pass Austin 78753 TX
Company Phone Number: 980-9190 Stock Exchange / Ticker: NASDAQ NTRA
|
2.08% 
98.1 %